Base de dados : LILACS
Pesquisa : D06.472.931.740.385 [Categoria DeCS]
Referências encontradas : 200 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 20 ir para página                         

  1 / 200 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1147475
Autor: Mijares Briñez, Alirio; Núñez, José M; Suárez, Carmen M; Bracamonte, Andreína.
Título: Hemiagenesia tiroidea: caso clínico y revisión de la literatura / Thyroid hemiagenesis: clinical case and review of the literature
Fonte: Rev. venez. oncol;33(1):33-39, mar. 2021. ilus.
Idioma: es.
Resumo: La hemiagenesia tiroidea representa un trastorno congénito caracterizado por la ausencia de desarrollo de uno de los lóbulos tiroideos, asociado o no a ausencia del istmo. Es más frecuente en las mujeres y por lo general se presenta como falta del lóbulo izquierdo, con hipertrofia compensatoria del lóbulo contralateral. Su diagnóstico es generalmente incidental o por manifestaciones del lóbulo tiroideo presente. Se hizo una revisión bibliografía, en donde no se encontraron casos reportados en Venezuela de hemiagenesia o agenesia tiroidea, describiéndose el siguiente. Presentamos a una paciente de 50 años de edad, conocida con hipotiroidismo desde los 31 años, negando cualquier cirugía en el área de cabeza y cuello. Desde febrero 2019 presentó aumento progresivo de volumen en región anterior de cuello. Al examen físico se observó aumento de volumen en región anterior derecha del cuello, palpándose lóbulo tiroideo derecho aumentado de tamaño, de aspecto nodular, no doloroso. En ecosonograma tiroideo se concluyó como bocio tiroideo derecho de aspecto multinodular, con ausencia del lóbulo izquierdo. Perfil tiroideo dentro de límites normales. Se lleva a mesa operatoria corroborándose ausencia del lóbulo izquierdo y presentado en la biopsia definitiva hiperplasia nodular en el lóbulo derecho. Se discute su frecuencia, la forma de presentación y se hace revisión de la literatura(AU)

Thyroid hemiagenesis represents a congenital disorder characterized by the absence of development of one of thyroid lobes, associated or not with absence of isthmus. It is more frequent in women and generally presents as absence of the left lobe, with compensatory hypertrophy of the contralateral lobe. Its diagnosis is generally incidental or by manifestations of the present thyroid lobe. A bibliography review was made, where no cases reported in Venezuela of hemiagenesis or thyroid agenesis were found, describing the following. We present a 50-year-old patient, known with hypothyroidism since she was 31, denying any surgery in the head and neck area. Since February 2019, presented a progressive increase in volume in the anterior neck region. On physical examination, an increase in volume was observed in right anterior region of the neck, palpating an enlarged right thyroid lobe, with a nodular appearance and not painful. In a thyroid echo-sonogram, it was concluded as a right thyroid goiter with a multinodular appearance, with the absence of the left lobe. Thyroid profile within normal limits. It is taken to the operating table, confirming the absence of the left lobe and presented in the definitive biopsy nodular hyperplasia in the right lobe. Its frequency, form of presentation, and literature review are discussed(AU)
Descritores: Glândula Tireoide/fisiopatologia
Bócio
Hipotireoidismo/cirurgia
-Doenças da Glândula Tireoide
Tri-Iodotironina
Ultrassonografia
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Revisão
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha


  2 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1124025
Autor: Benozzi, Silvia Fabiana; Unger, Gisela; Milano, Pablo Gustavo; Campion, Amparo; Pennacchiotti, Graciela Laura.
Título: Tomar mate previo a la flebotomía no interfiere en las pruebas bioquímicas de rutina / Drinking mate prior to phlebotomy does not interfere with routine biochemical tests
Fonte: Acta bioquím. clín. latinoam;53(4):477-486, dic. 2019. graf, tab.
Idioma: es.
Resumo: En este estudio se evaluó el efecto de tomar mate en las pruebas bioquímicas de rutina. Se extrajo sangre a 32 mujeres voluntarias luego de 12 horas de ayuno y a la hora (T1), dos horas (T2) y tres horas (T3) posteriores a la toma de 5 mates. Se estudiaron parámetros hematológicos y analitos de química clínica. Los resultados se analizaron empleando pruebas estadísticas para muestras relacionadas. Se calculó la diferencia porcentual media (DM%) de cada analito en cada hora respecto del valor basal y se comparó con el valor de referencia del cambio (VRC). Una DM% mayor que el VRC se consideró clínicamente significativa. En T1, T2 y T3 los recuentos de neutrófilos, eosinófilos y linfocitos fueron más bajos que en T0, también los niveles de glucosa, urea, creatinina y cistatina C fueron más bajos que en T0, mientras que los valores de proteínas totales, colesterol transportado por lipoproteínas de baja densidad y la actividad enzimática de lactato deshidrogenasa fueron más altos que en T0. En todos los casos los cambios fueron estadísticamente significativos, aunque no lo fueron desde el punto de vista clínico. Tomar 5 mates antes de la flebotomía no interfiere en los resultados de las pruebas bioquímicas de rutina.

In the present study the effect of drinking mate in routine biochemical tests was evaluated. Blood was collected from 32 female volunteers after a 12 h fasting period. In addition, 1 hour (T1), 2 hours (T2), and 3 hours (T3) after drinking 5 mates, blood was collected again. Hematological parameters and clinical chemistry analytes were studied. The results were analyzed using statistical tests for related samples. Mean difference % (MD%) was calculated for each analyte and was further compared with reference change value (RCV). The MDs% higher than RCV were considered clinically significant. At T1, T2, and T3 the count neutrophils, eosinophils and lymphocytes were lower than at T0. Also glucose, urea, creatinine, and cystatin C values were lower than at T0 whereas total proteins, LDL-C, and LD enzymatic activity values were higher than at T0. In all cases, variability was statistically significant but not clinically significant. Drinking 5 mates prior to phlebotomy does not interfere with the results of routine biochemical tests.

Neste trabalho, o efeito de beber chimarrão foi avaliado em testes bioquímicos de rotina. O sangue foi extraído de 32 mulheres voluntárias após 12 horas de jejum, e uma hora (T1), duas horas (T2) e três horas (T3) após a tomada de 5 chimarrões. Parâmetros hematológicos e analitos de química clínica foram estudados. Os resultados foram analisados utilizando testes estatísticos para amostras relacionadas. A diferença percentual média% (DM%) de cada analito em cada hora foi calculada em relação ao valor basal e comparada com o valor de referência da modificação (VRM). Uma DM% maior que o VRM foi considerada clinicamente significativa. Em T1, T2 e T3 as contagens de neutrófilos, eosinófilos e linfócitos foram mais baixas que em T0, Também os níveis de glicose, ureia, creatinina e cistatina C foram mais baixos que em T0, ao passo que os valores de proteínas totais, colesterol transportado por lipoproteínas de baixa densidade e a atividade enzimática de lactato desidrogenase foram mais altos que em T0. Em todos os casos as alterações foram estatisticamente significativas, embora do ponto de vista clínico não o tenham sido. Tomar 5 chimarrões antes da flebotomia não interfere nos resultados dos testes bioquímicos de rotina.
Descritores: Ureia
Sangue
Linfócitos
Química Clínica
Jejum
Flebotomia
Creatinina
Ingestão de Líquidos
Cistatina C
Fase Pré-Analítica/métodos
Glucose
Lipoproteínas LDL
-Encaminhamento e Consulta
Rutina
Tri-Iodotironina
Mulheres
Colesterol
Coleta de Dados
Eosinófilos
Parâmetros
Fase Pré-Analítica/estatística & dados numéricos
L-Lactato Desidrogenase
Neutrófilos
Limites: Humanos
Tipo de Publ: Artigo Clássico
Responsável: AR144.1 - CIBCHACO - Centro de Información Biomedica del Chaco


  3 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1128985
Autor: Scheinfeld, Ester Gabriela; Lovazzano, Soledad; Ramajo, María Fernanda.
Título: Endocrinopatías por inmunoterapia oncológica / Endocrinopathies by oncological immunotherapy
Fonte: Rev. Hosp. Ital. B. Aires (2004);40(3):95-104, sept. 2020. ilus, tab.
Idioma: es.
Resumo: La relación entre inmunidad y cáncer es compleja. Las células tumorales desarrollan mecanismos de evasión a las respuestas del sistema inmunitario. Esta capacidad permite su supervivencia y crecimiento. La inmunoterapia ha transformado el tratamiento oncológico mejorando la respuesta inmunitaria contra la célula tumoral. Esta se basa en el bloqueo de los puntos de control inmunitario mediante anticuerpos monoclonales contra la molécula inhibidora CTLA-4 (antígeno 4 del linfocito T citotóxico [CTLA-4]) y la proteína 1 de muerte celular programada y su ligando (PD-1/PD-L1). Aunque los inhibidores de los puntos de control inmunitario (ICIs) son fármacos bien tolerados, tienen un perfil de efectos adversos conocido como eventos adversos inmunorrelacionados (EAI). Estos afectan varios sistemas, incluyendo las glándulas endocrinas. Los eventos adversos endocrinos más frecuentes son la disfunción tiroidea, la insuficiencia hipofisaria, la diabetes mellitus autoinmune y la insuficiencia suprarrenal primaria. El creciente conocimiento de estos efectos adversos endocrinos ha llevado a estrategias de tratamiento efectivo con el reemplazo hormonal correspondiente. El objetivo de esta revisión es reconocer la incidencia de estas nuevas endocrinopatías, la fisiopatología, su valoración clínica y el manejo terapéutico. (AU)

The relationship between immunity and cancer is complex. Tumor cells develop evasion mechanisms to the immune system responses. This ability allows their survival and progression. Immunotherapy has transformed cancer treatment by improving the immune response against tumor cells. This is achieved by blocking immune checkpoints with monoclonal antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 and its ligand (PD-1 / PD-L1). Although the immune checkpoint inhibitors (ICIs) are well tolerated drugs, they have a profile of adverse effects known as immune-related adverse events (irAES). These involve diverse systems, including the endocrine glands. The most frequent endocrine immune-related adverse events are thyroid and pituitary dysfunction, autoimmune diabetes mellitus and primary adrenal insufficiency. The increasing knowledge of these irAES has led to effective treatment strategies with the corresponding hormonal replacement. The objective of this review is to recognize the incidence of these new endocrinopathies, the physiopathology, their clinical evaluation, and therapeutic management. (AU)
Descritores: Doenças do Sistema Endócrino/induzido quimicamente
Imunoterapia/efeitos adversos
-Doenças da Glândula Tireoide/diagnóstico
Doenças da Glândula Tireoide/induzido quimicamente
Doenças da Glândula Tireoide/patologia
Doenças da Glândula Tireoide/terapia
Tiroxina/administração & dosagem
Tri-Iodotironina/uso terapêutico
Corticosteroides/administração & dosagem
Insuficiência Adrenal/diagnóstico
Insuficiência Adrenal/induzido quimicamente
Insuficiência Adrenal/patologia
Insuficiência Adrenal/terapia
Diabetes Mellitus Tipo 1/diagnóstico
Diabetes Mellitus Tipo 1/induzido quimicamente
Diabetes Mellitus Tipo 1/patologia
Diabetes Mellitus Tipo 1/terapia
Doenças do Sistema Endócrino/diagnóstico
Doenças do Sistema Endócrino/fisiopatologia
Doenças do Sistema Endócrino/terapia
Hipofisite/diagnóstico
Hipofisite/induzido quimicamente
Hipofisite/patologia
Hipofisite/terapia
Glucocorticoides/administração & dosagem
Insulina/uso terapêutico
Metimazol/uso terapêutico
Mineralocorticoides/uso terapêutico
Anticorpos Monoclonais/uso terapêutico
Neoplasias/imunologia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: AR2.1 - Biblioteca Central


  4 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827785
Autor: Kaminski, Juliana; Miasaki, Fabíola Yukiko; Paz-Filho, Gilberto; Graf, Hans; Carvalho, Gisah Amaral de.
Título: Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study
Fonte: Arch. endocrinol. metab. (Online);60(6):562-572, Nov.-Dec. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3) therapy in patients with primary hypothyroidism. Subjects and methods This is a randomized, double-blind, crossover study. Adults with primary hypothyroidism (n = 32, age 42.6 ± 13.3, 30 females) on stable doses of LT4 for ≥ 6 months (125 or 150 μg/day) were randomized to continue LT4 treatment (G1) or to start LT4/LT3 therapy (75/15 μg/day; G2). After 8 weeks, participants switched treatments for 8 more weeks. Thyroid function, lipid profile, plasma glucose, body weight, electrocardiogram, vital signs, and quality of life (QoL) were evaluated at weeks 0, 8 and 16. Results Free T4 levels were significantly lower while on LT4/LT3 (G1: 1.07 ± 0.29 vs. 1.65 ± 0.46; G2: 0.97 ± 0.26 vs. 1.63 ± 0.43 ng/dL; P < 0.001). TSH and T3 levels were not affected by type of therapy. More patients on LT4/LT3 had T3 levels above the upper limit (15% vs. 3%). The combination therapy led to an increase in heart rate, with no significant changes in electrocardiogram or arterial blood pressure. Lipid profile, body weight and QoL remained unchanged. Conclusions The combination therapy yielded significantly lower free T4 levels, with no changes in TSH or T3 levels. More patients on LT4/T3 had elevated T3 levels, with no significant alterations in the evaluated outcomes. No clear clinical benefit of the studied formulation could be observed. Future trials need to evaluate different formulations and the impact of the combined therapy in select populations with genetic polymorphisms.
Descritores: Tiroxina/uso terapêutico
Tri-Iodotironina/uso terapêutico
Hipotireoidismo/tratamento farmacológico
-Qualidade de Vida
Testes de Função Tireóidea
Tiroxina/sangue
Tiroxina/farmacologia
Tri-Iodotironina/sangue
Tri-Iodotironina/farmacologia
Glicemia/análise
Peso Corporal/efeitos dos fármacos
Tireotropina/efeitos dos fármacos
Colesterol/sangue
Método Duplo-Cego
Estudos Cross-Over
Combinação de Medicamentos
Hipotireoidismo/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  5 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827786
Autor: Campanha, Fábio V G; Perone, Denise; Campos, Dijon H S de; Luvizotto, Renata de A M; De Síbio, Maria T; Oliveira, Miriane de; Olimpio, Regiane M C; Moretto, Fernanda C F; Padovani, Carlos R; Mazeto, Gláucia M F S; Cicogna, Antonio C; Nogueira, Célia R.
Título: Thyroxine increases Serca2 and Ryr2 gene expression in heart failure rats with euthyroid sick syndrome
Fonte: Arch. endocrinol. metab. (Online);60(6):582-586, Nov.-Dec. 2016. tab, graf.
Idioma: en.
Projeto: Fapesp.
Resumo: ABSTRACT Objective The current study was aimed at analyzing sarcoplasmic reticulum Ca2+ ATPase (Serca2) and ryanodine receptor type 2 (Ryr2) gene expression in rats subjected to surgery that induced HF and were subsequently treated with T4 using physiological doses. Materials and methods HF was induced in 18 male Wistar rats by clipping the ascending thoracic aorta to generate aortic stenosis (HFS group), while the control group (9-sham) underwent thoracotomy. After 21 weeks, the HFS group was subdivided into two subgroups. One group (9 Wistar rats) with HF received 1.0 µg of T4/100 g of body weight for five consecutive days (HFS/T4); the other group (9 Wistar rats) received isotonic saline solution (HFS/S). The animals were sacrificed after this treatment and examined for signs of HF. Samples from the left ventricles of these animals were analyzed by RT-qPCR for the expression of Serca2 and Ryr2 genes. Results Rats with HF developed euthyroid sick syndrome (ESS) and treatment with T4 restored the T3 values to the Sham level and increased Serca2 and Ryr2 gene expression, thereby demonstrating a possible benefit of T4 treatment for heart function in ESS associated with HF. Conclusion The T4 treatment can potentially normalize the levels of T3 as well elevated Serca2 and Ryr2 gene expression in the myocardium in heart failure rats with euthyroid sick syndrome.
Descritores: Tiroxina/administração & dosagem
Síndromes do Eutireóideo Doente/tratamento farmacológico
Canal de Liberação de Cálcio do Receptor de Rianodina/efeitos dos fármacos
-Estenose da Valva Aórtica/complicações
Tiroxina/uso terapêutico
Tri-Iodotironina/efeitos dos fármacos
Síndromes do Eutireóideo Doente/complicações
Síndromes do Eutireóideo Doente/genética
RNA Mensageiro/metabolismo
Expressão Gênica/efeitos dos fármacos
Ratos Wistar
Canal de Liberação de Cálcio do Receptor de Rianodina/genética
Modelos Animais
ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/efeitos dos fármacos
ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/genética
Insuficiência Cardíaca/complicações
Limites: Animais
Masculino
Responsável: BR1.1 - BIREME


  6 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-838410
Autor: Angelousi, Anna; Diamanti-Kandarakis, Evanthia; Zapanti, Evangelia; Nonni, Afroditi; Ktenas, Eftuxios; Mantzou, Aimilia; Kontzoglou, Konstantinos; Kouraklis, Grigorios.
Título: Is there an association between thyroid function abnormalities and breast cancer?
Fonte: Arch. endocrinol. metab. (Online);61(1):54-61, Jan.-Feb. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective The aim of this study was to evaluate the association between thyroid function abnormalities and breast cancer and, in particular, the prognostic markers of breast cancer.. Subjects and methods Baseline levels of thyrotropin, free triiodothyronine, free thyroxine and thyroid autoantibodies were measured in 97 women with primary breast cancer, 27 women with benign breast disease, and 4 women with atypical ductal hyperplasia. Their baseline levels were compared with those in 48 healthy women with a normal mammography in the last 2 years. Results There were no significant associations between history of thyroid disease and breast cancer (p = 0.33). The mean baseline levels of triiodothyronine and thyrotropin did not differ significantly between the compared groups. The mean baseline levels of free thyroxine were found to be significantly higher in the breast cancer group, even after adjusting for thyroid replacement therapy. The presence of thyroid antibodies did not differ significantly between the compared groups. In a subgroup analysis, breast cancer cases with thyroid disease and particularly hypothyroidism had a significantly lower incidence of lymph node metastases compared with breast cancer cases without thyroid disease. Conclusions Our data confirmed the proliferative effect of thyroid hormones on breast cells, which had previously been shown in vitro. Additionally, thyroid disease and particularly hypothyroid function appeared to be associated with a lower incidence of lymph node metastases. Further studies to determine the prognostic role of thyroid hormones in breast cancer are warranted.
Descritores: Glândula Tireoide/fisiopatologia
Neoplasias da Mama/complicações
Biomarcadores/sangue
-Prognóstico
Autoanticorpos/sangue
Glândula Tireoide/irrigação sanguínea
Tiroxina/sangue
Tri-Iodotironina/sangue
Neoplasias da Mama/fisiopatologia
Neoplasias da Mama/sangue
Tireotropina/sangue
Imuno-Histoquímica
Estudos de Casos e Controles
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  7 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-950084
Autor: Nakova, Valentina Velkoska; Krstevska, Brankica; Kostovska, Elizabeta Srbinovska; Vaskova, Olivija; Ismail, Ljubica Georgievska.
Título: The effect of levothyroxine treatment on left ventricular function in subclinical hypothyroidism
Fonte: Arch. endocrinol. metab. (Online);62(4):392-398, July-Aug. 2018. tab.
Idioma: en.
Resumo: ABSTRACT Objective: Treatment of subclinical hypothyroidism (ScH), especially the mild form of ScH, is controversial because thyroid hormones influence cardiac function. We investigate left ventricular systolic and diastolic function in ScH and evaluate the effect of 5-month levothyroxine treatment. Subjects and methods: Fifty-four patients with newly diagnosed mild ScH (4.2 <TSH < 10.0 mU/L) and 30 euthyroid subjects matched by age were analysed. Laboratory analyses and an echocardiography study were done at the first visit and after 5 months in euthyroid stage in patients with ScH. Results: Compared to healthy controls, patients with ScH had a lower E/A ratio (1.03 ± 0.29 vs. 1.26 ± 0.36, p < 0.01), higher E/e' sep. ratio (762 ± 2.29 vs. 6.04 ± 1.64, p < 0.01), higher myocardial performance index (MPI) (0.47 ± 0.08 vs. 0.43 ± 0.07, p < 0.05), lower global longitudinal strain (GLS) (-19.5 ± 2.3 vs. −20.9 ± 1.7%, p < 0.05), and lower S wave derived by tissue Doppler imaging (0.077 ± 0.013 vs. 0.092 ± 0.011 m/s, p < 0.01). Levothyroxine treatment in patients with ScH contributed to higher EF (62.9 ± 3.9 vs. 61.6 ± 4.4%, p < 0.05), lower E/e' sep. ratio (6.60 ± 2.06 vs. 762 ± 2.29, p < 0.01), lower MPI (0.43 ± 0.07 vs. 0.47 ± 0.08%, p < 0.01), and improved GLS (-20.07 ± 2.7 vs. −19.55 ± 2.3%, p < 0.05) compared to values in ScH patients at baseline. Furthermore, in all study populations (ScH patients before and after levothyroxine therapy and controls), TSH levels significantly negatively correlated with EF (r = −0.15, p < 0.05), E/A (r = −0.14, p < 0.05), GLS (r = −0.26, p < 0.001), and S/TDI (r = −0.22, p < 0.01) and positively correlated with E/e' sep. (r = 0.14, p < 0.05). Conclusion: Patients with subclinical hypothyroidism versus healthy individuals had subtle changes in certain parameters that indicate involvement of systolic and diastolic function of the left ventricle. Although the values of the parameters were in normal range, they were significantly different compared to ScH and the control group at baseline, as well as to the ScH groups before and after treatment.The results of our study suggest that patients with ScH must be followed up during treatment to assess improvement of the disease. Some of the echocardiography obtained parameters were reversible after levothyroxine therapy.
Descritores: Sístole/efeitos dos fármacos
Tiroxina/farmacologia
Função Ventricular Esquerda/efeitos dos fármacos
Diástole/efeitos dos fármacos
Hipotireoidismo/tratamento farmacológico
-Sístole/fisiologia
Tiroxina/administração & dosagem
Tiroxina/sangue
Tiroxina/uso terapêutico
Tri-Iodotironina/sangue
Tireotropina/sangue
Estudos de Casos e Controles
Estudos Prospectivos
Ecocardiografia Doppler de Pulso
Diástole/fisiologia
Ventrículos do Coração/fisiopatologia
Ventrículos do Coração/diagnóstico por imagem
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Tipo de Publ: Estudo Multicêntrico
Responsável: BR1.1 - BIREME


  8 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-950086
Autor: Ortolani Jr, Pedro D; Romaldini, João H; Guerra, Ricardo A; Portes, Evandro S; Meireles, George C X; Pimenta, João.
Título: Association of serum thyrotropin levels with coronary artery disease documented by quantitative coronary angiography: a transversal study
Fonte: Arch. endocrinol. metab. (Online);62(4):410-415, July-Aug. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: The association between coronary artery disease (CAD) and thyroid function remains controversial. We evaluated the thyroid function and graduated well-defined CAD as confirmed by quantitative coronary angiography (CA). Subjects and methods: We evaluated the serum TSH, free thyroxine, free triiodothyronine and thyroid antibody levels in 300 consecutive patients (age 61.6 ± 9.9 years and 54% were male) undergoing CAD diagnosis as confirmed by CA. Plaques with ≥ 50% stenosis being indicative of obstructive CAD, and patients were divided into groups according to main epicardial coronary arteries with plaques (0, 1, 2, 3). Lipid profiles and a homeostasis model assessment (HOMA-IR) were determined. Results: Serum median (25% and 75% percentile) TSH levels in patients with group 2 and 3 (2.25; 1.66-3.12 mU/L and 4.99; 4.38-23.60 mU/L, respectively) had significantly higher TSH concentrations (p < 0.0001) than the group 0 (1.82; 1.35-2.51 mU/L). Furthermore, patients of group 3 had higher TSH concentration (p < 0.0001) than those of group 1 (1.60; 0.89-2.68 mU/L). Group 3 were older (64 ± 8.5 vs. 59 ± 9.5, p = 0.001), had more patients with dyslipidemia (84% versus 58%, p < 0.001), male (54% versus 44%, p = 0.01), hypertension (100% versus 86%, p < 0.001), and smoking (61% versus 33%, p < 0.001) than group 0. Multivariate stepwise logistic analysis showed TSH, age, HbA1c, and HOMA-IR were the CAD associated variables. Conclusions: In this cohort, elevated TSH levels in the high normal range or above are associated with the presence and severity of CAD besides may represent a weak CAD risk factor.
Descritores: Doença da Artéria Coronariana/sangue
Tireotropina/sangue
-Testes de Função Tireóidea
Tiroxina/sangue
Tri-Iodotironina/sangue
Doença da Artéria Coronariana/diagnóstico por imagem
Hemoglobina A Glicada/análise
Resistência à Insulina
Colesterol/sangue
Estudos Transversais
Fatores de Risco
Fatores Etários
Angiografia Coronária
Estenose Coronária/diagnóstico por imagem
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  9 / 200 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-983815
Autor: Gonzalez-Aguilera, Beatriz; Betea, Daniela; Lutteri, Laurence; Cavalier, Etienne; Geenen, Vincent; Beckers, Albert; Valdes-Socin, Hernan.
Título: Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients
Fonte: Arch. endocrinol. metab. (Online);62(6):609-614, Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: The conversion of Hashimoto's thyroiditis (HT) to hyperthyroidism due to thyrotropin receptor antibodies is intriguing and considered rare. The contribution of TSH receptor blocking antibodies (TRAb), which may be stimulators (TSAb) or blockers (TBAb), is suspected. We describe clinical and biological variables in a series of patients switching from Hashimoto's thyroiditis to Grave's disease. Subjects and methods: Retrospective case study of 24 patients with Hashimoto's thyroiditis followed during 48 ± 36 months that developed later Graves' disease (GD). These variables were analysed in the hypo and hyperthyroid phase: age, sex, initial TSH, free triiodothyronine (fT3), free thyroxine (fT4), anti-TPO, TBII antibodies, parietal cell autoantibodies, time between hypo and hyperthyroidism, thyroid volume and levothyroxine doses (LT). Results: In HT, mean TSH was 9.4 ± 26.1 UI/L and levothyroxine treatment was 66.2 ± 30.8 µg/day. The switch to GD was observed 38 ± 45 months after HT diagnosis. As expected, we found significant differences on TSH, FT3, FT4 and TBAb levels. Three out of 14 patients had parietal cell autoantibodies. In two of these three cases there was an Helicobacter pylori infection. There were no significant differences between HT and GD groups with respect to thyroid volume. Conclusions: To our knowledge, large series documenting the conversion of HT to GD are scarce. Although rare, this phenomenon should not be misdiagnosed. Suspicion should be raised whenever thyroxine posology must be tapered down during the follow-up of HT patients. Further immunological and genetic studies are needed to explain this unusual autoimmune change.
Descritores: Receptores da Tireotropina/imunologia
Doença de Graves/imunologia
Doença de Hashimoto/imunologia
-Autoanticorpos/imunologia
Testes de Função Tireóidea
Tiroxina/administração & dosagem
Tiroxina/sangue
Tri-Iodotironina/sangue
Receptores da Tireotropina/sangue
Tireotropina/sangue
Doença de Graves/sangue
Estudos Retrospectivos
Estatísticas não Paramétricas
Imunoglobulinas Glândula Tireoide-Estimulantes/imunologia
Doença de Hashimoto/sangue
Hipotireoidismo/imunologia
Medições Luminescentes
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  10 / 200 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001213
Autor: Silva, Tabata M; Moretto, Fernanda C F; Sibio, Maria T De; Gonçalves, Bianca M; Oliveira, Miriane; Olimpio, Regiane M C; Oliveira, Diego A M; Costa, Sarah M B; Deprá, Igor C; Namba, Vickeline; Nunes, Maria T; Nogueira, Célia R.
Título: Triiodothyronine (T3) upregulates the expression of proto-oncogene TGFA independent of MAPK/ERK pathway activation in the human breast adenocarcinoma cell line, MCF7
Fonte: Arch. endocrinol. metab. (Online);63(2):142-147, Mar.-Apr. 2019. graf.
Idioma: en.
Projeto: FAPESP.
Resumo: ABSTRACT Objective: To verify the physiological action of triiodothyronine T3 on the expression of transforming growth factor α (TGFA) mRNA in MCF7 cells by inhibition of RNA Polymerase II and the MAPK/ERK pathway Materials and methods: The cell line was treated with T3 at a physiological dose (10−9M) for 10 minutes, 1 and 4 hour (h) in the presence or absence of the inhibitors, α-amanitin (RNA polymerase II inhibitor) and PD98059 (MAPK/ERK pathway inhibitor). TGFA mRNA expression was analyzed by RT-PCR. For data analysis, we used ANOVA, complemented with the Tukey test and Student t-test, with a minimum significance of 5%. Results: T3 increases the expression of TGFA mRNA in MCF7 cells in 4 h of treatment. Inhibition of RNA polymerase II modulates the effect of T3 treatment on the expression of TGFA in MCF7 cells. Activation of the MAPK/ERK pathway is not required for T3 to affect the expression of TGFA mRNA. Conclusion: Treatment with a physiological concentration of T3 after RNA polymerase II inhibition altered the expression of TGFA. Inhibition of the MAPK/ERK pathway after T3 treatment does not interfere with the TGFA gene expression in a breast adenocarcinoma cell line.
Descritores: Tri-Iodotironina/genética
Neoplasias da Mama/genética
Adenocarcinoma/genética
Regulação Neoplásica da Expressão Gênica/genética
Fator de Crescimento Transformador alfa/genética
Sistema de Sinalização das MAP Quinases/genética
-Tri-Iodotironina/metabolismo
Tri-Iodotironina/farmacologia
Proto-Oncogenes/genética
Neoplasias da Mama/metabolismo
RNA Mensageiro/genética
Adenocarcinoma/metabolismo
Fator de Crescimento Transformador alfa/efeitos dos fármacos
Fator de Crescimento Transformador alfa/metabolismo
Linhagem Celular Tumoral/metabolismo
Células MCF-7/metabolismo
Limites: Humanos
Feminino
Responsável: BR1.1 - BIREME



página 1 de 20 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde